Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 10,856 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Duchenne Muscular Dystrophy (DMD), Cardiomyopathy
Interventions: Losartan, Lisinopril; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Davis, California • Kansas City, Kansas • Boston, Massachusetts + 3 more

Conditions: Tibial Delayed Healing
Interventions: INFUSE/MASTERGRAFT, Autograft bone; Device · Procedure
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 21 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Denver, Colorado • Fort Lauderdale, Florida • Jacksonville, Florida + 13 more

Conditions: Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions: Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 390
States / cities: Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more

Conditions: HIV Infections
Interventions: Hydroxyurea, Efavirenz, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 19
States / cities: Menlo Park, California • San Jose, California • Stanford, California + 9 more

Conditions: Dysphagia, Oropharyngeal
Interventions: Videofluoroscopic Swallowing Study (VF); Diagnostic Test
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years and older
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Gainesville, Florida • Cincinnati, Ohio • Columbus, Ohio

Conditions: Crohn Disease
Interventions: Etrolizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 62
States / cities: Arcadia, California • La Jolla, California • Long Beach, California + 53 more

Conditions: Sickle Cell Trait
Interventions: Education; Other
Lead sponsor: Susan Creary; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Myelodysplastic Syndrome
Interventions: Oral Azacitidine, Placebo, Best Supportiv Care (BSC); Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 40
States / cities: Berkeley, California • Beverly Hills, California • Duarte, California + 31 more

Conditions: Leukemia
Interventions: clofarabine, cytarabine, methotrexate, laboratory biomarker analysis; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 74
States / cities: Birmingham, Alabama • Downey, California • Long Beach, California + 65 more

Conditions: Alzheimers Disease
Interventions: CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum; Biological · Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 78
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more

Conditions: Localized Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
Interventions: Interview, Nutritional Therapy, Physical Therapy, Psychosocial Care, Questionnaire Administration; Other · Procedure · Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Heart Failure, Congestive
Interventions: Seloken ZOK/Toprol-XL, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 44
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 41 more

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: Not listed
Lead sponsor: Disarm Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: DeBary, Florida • Baltimore, Maryland • Ann Arbor, Michigan + 6 more

Conditions: Postmenopausal Osteoporosis
Interventions: Ibandronate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Female only
Enrollment: 1,711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 142
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 128 more

Conditions: Non-small Cell Lung Cancer
Interventions: Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Anchorage, Alaska • Beverly Hills, California • Los Angeles, California + 17 more

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: Myelofibrosis
Interventions: Fludarabine, Melphalan +/- ATG; Drug
Lead sponsor: John Mascarenhas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 7
States / cities: Chicago, Illinois • Baltimore, Maryland • Buffalo, New York + 3 more

Conditions: Pulmonary Embolism and Thrombosis
Interventions: EkoSonic Endovascular System with thrombolytic; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 65
States / cities: Glendale, Arizona • Los Angeles, California • Englewood, Colorado + 54 more

Conditions: Chronic Kidney Diseases, Pruritus
Interventions: Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 83
States / cities: Huntsville, Alabama • Phoenix, Arizona • Surprise, Arizona + 76 more

Conditions: Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Regional Gastrointestinal Carcinoid Tumor, Somatostatinoma
Interventions: romidepsin, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Generalized Myasthenia Gravis
Interventions: Zilucoplan; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: New Haven, Connecticut • Tampa, Florida • Columbia, Missouri + 4 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BI 1015550, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more

Conditions: Vaginal Infection
Interventions: Metronidazole, Gel vehicle; Drug
Lead sponsor: Curatek Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 28 more

Conditions: Hearing Loss, Cochlear Trauma
Interventions: Ebselen, Placebo; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 6
States / cities: Iowa City, Iowa • Columbus, Ohio • Philadelphia, Pennsylvania + 3 more

Search by objective public record fields.

Cardiomyopathy in DMD: Lisinopril vs. Losartan

Tibial Delayed Healing Pivotal Clinical Trial

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible

Reference Values for Videofluoroscopic Measures of Swallowing

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

A Program to Increase Sickle Cell Trait Knowledge Among Parent of Young Children Identified in Newborn Screening

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer

Reversal of Ventricular Remodeling With Toprol-XL

Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

An International Pulmonary Embolism Registry Using EKOS

A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Multi-Center Study of New Medications to Treat Vaginal Infections

SPI-1005 in Adults Receiving Cochlear Implant